human health image

Clinical diagnostics are moving towards minimally-invasive procedures that allow the early detection of disease, as well as monitoring of disease status and treatment efficacy. These methods rely on the ability to detect “red flags” of diseases, referred as biomarkers, in body fluids from patients. Given the relatively new field of extracellular vesicles (EVs) study, data is now emerging on their characteristics and functions. These recently identified nanoparticles contain a sample of material found in the diseased cells of the patients and are a promising source of biomarkers in biological fluids.

However, there are currently obstacles to the application of EVs in the clinical setting which include the quick and robust isolation of required quantities of EVs from various body fluids as well as the enrichment of EVs from diseased cells among mixtures of vesicular material originating from multiple cell types.

The promising characteristics of EVs make them a fast growing area of research and translational medicine due to their applications in areas where repetitive and non-invasive collection and analysis of biomarkers from biological fluids is desired. Therefore, there is a pressing need to develop rapid and versatile disease-specific EV isolation and diagnostic technologies.

We can offer you access to the Vn96 platform technology to overcome many of these challenges by isolating and purifying specific EVs originating from diseased cells, minimizing process time and using existing infrastructure. Yields of EVs purified using Vn96 prove to be better than other established methods of EV isolation, as evaluated by protein content and nanoparticle tracking analysis.

Benefits of using the Vn96 isolation technology include

  • Use in diagnostics, monitoring of disease status and treatment efficacy
  • Sample analysis from biological fluids
  • Non-invasive or minimally-invasive
  • No need for ultracentrifuge
  • Sample processing in minutes versus hours

Vn96 may be used in the development of early-diagnostic tools for

  • Cancer
  • Cardiovascular diseases
  • Neurodegenerative diseases
  • Metabolic diseases
  • Other diseases

This email address is being protected from spambots. You need JavaScript enabled to view it.

Excipio Technologies Inc.

35 Providence Street
Moncton, New Brunswick
E1C 8X3
Canada
info@excipio.ca

METM Kit product information:
sales@newenglandpeptide.com

Business Development Contact:
Remi Richard
Business Development Agent
remi.richard@canceratl.ca
Phone : +1 506 869 2048
Fax : +1 506 862 7571

Unlock the diagnostic potential of exosomes

Increase the specificity and sensitivity of your biofluid-based molecular diagnostic assays with Vn96. The Vn96 platform technology can give you access to improved clinical diagnostics directly on site or at point-of-care with faster, more specific and efficient exosome isolation. All while using your existing infrastructure, minimizing your isolation time to less than an hour and eliminating the need for ultracentrifugation or expensive antibodies and filtration methods.
logo iarc logo nep

Follow us

icon facebook off icon linkedin off icon youtube off icon google off icon twitter off